CI-988

CI-988

Chemical structure of CI-988

CI-988 is a pharmacological compound that acts as a selective antagonist of the cholecystokinin (CCK) receptor, specifically the CCK_A receptor subtype. It has been studied for its potential therapeutic applications in various neurological and psychiatric disorders.

Mechanism of Action

CI-988 functions by inhibiting the action of the neurotransmitter cholecystokinin at the CCK_A receptors. These receptors are primarily located in the gastrointestinal tract and the central nervous system. By blocking these receptors, CI-988 can modulate the effects of cholecystokinin, which is involved in processes such as anxiety, pain perception, and appetite regulation.

Potential Therapeutic Uses

Anxiety Disorders

CI-988 has been investigated for its potential use in treating anxiety disorders. The blockade of CCK_A receptors may reduce anxiety symptoms, as cholecystokinin is known to play a role in the modulation of anxiety.

Pain Management

The compound has also been studied for its analgesic properties. By antagonizing CCK_A receptors, CI-988 may enhance the effects of opioids and reduce pain perception, offering a potential adjunctive treatment in pain management.

Appetite Regulation

Cholecystokinin is involved in the regulation of appetite and satiety. CI-988's action on CCK_A receptors suggests it could influence eating behaviors and potentially be used in the treatment of obesity or eating disorders.

Pharmacokinetics

CI-988 is administered orally and undergoes metabolism in the liver. Its pharmacokinetic profile includes a moderate half-life, allowing for potential therapeutic use with manageable dosing schedules.

Research and Development

Research on CI-988 has primarily been conducted in preclinical and early clinical trials. While results have shown promise, further studies are needed to fully understand its efficacy and safety profile in humans.

Related Pages

• Cholecystokinin
• Receptor antagonist
• Anxiety disorder
• Pain management
• Appetite regulation